Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
Royal North Shore Hospital, Sydney, Australia.
Nicholas F
NF
Blair
Bruce J
BJ
Brew
Jean-Pierre
JP
Halpern
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D004569:Electroencephalography; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000150:complications; D016899:Interferon-beta / Q000627:therapeutic use; D007577:JC Virus / Q000276:immunology; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy; D000069442:Natalizumab; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D016899:Interferon-beta; D008775:Methylprednisolone